Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DHNP-2023
- Development stage
- Preclinical
- Lead developer
- Daehan Nupharm
- Modality
- Small Molecules
01
Overview
DHNP-2023 is a small molecule drug candidate being developed by the South Korean pharmaceutical company Daehan Nupharm. It is currently in the formulation research stage for the treatment of both epilepsy and obesity. The drug is classified in the company's pipeline as an incrementally modified drug (IMD), suggesting it may be a new dosage form, salt, or delivery method of an existing active ingredient intended to improve therapeutic outcomes, safety, or patient compliance. While the specific chemical identity and molecular targets have not been publicly disclosed by the developer, the dual indication of epilepsy and obesity is characteristic of certain neuromodulatory agents or carbonic anhydrase inhibitors.
Beyond the preview
Go deeper on DHNP-2023.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DHNP-2023.